Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia

Name: Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
Published: 2022
License: Public Domain

KK Women's and Children's Hospital · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

acute car childhood

lymphoblastic leukemia, lymphoblastic leukemia, acute, childhood, lymphoblastic leukemia in children, lymphoblastic leukemia, acute adult, car, car t-cell therapy, b-all, relapsed/ refractory, interventional, phase1, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia

Related documents